相关实验视频
Updated: Jun 14, 2025
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
10.8K
雄激素受体单体和双体调节前列腺癌细胞中相反的生物过程
Rachid Safi1, Suzanne E Wardell1, Paige Watkinson1
1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Nature communications
|September 3, 2024
概括
在前列腺癌中,较低的雄激素水平通过雄激素受体 (AR) 单体激活mTOR信号传递和扩散. 高剂量的雄激素通过形成AR二聚体/寡聚体来抑制扩散,为前列腺癌和雄激素病变揭示了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 前列腺癌 (PCa) 的生长通常由雄激素受体 (AR) 信号轴驱动.
- 目前的疗法旨在抑制AR信号,但矛盾的是,高剂量的雄激素可以在晚期PCa中有效.
- 在PCa中雄激素的双重作用需要更深入地了解AR信号动态.
研究的目的:
- 调查低剂量和高剂量的雄激素影响前列腺癌细胞增殖的独特机制.
- 阐明雄激素受体 (AR) 单体与二聚体/寡聚体形成在调解这些效应中的作用.
- 确定前列腺癌和其他与雄激素有关的疾病的新型治疗点和策略.
主要方法:
- 在不同度的雄激素受体 (AR) 信号通路的分析.
- 研究非基因组和基因组激活途径.
- 评估细胞增殖,基因表达 (例如,c-MYC) 和AR形态状态 (单质与二元/寡质).
主要成果:
- 较低的雄激素水平通过AR单体介导的mTOR通路的非基因组激活促进PCa的扩散.
- 高剂量的雄激素诱导AR二聚体/寡聚体的形成,导致c-MYC抑制,增殖抑制和差异化转录程序.
- 这些发现揭示了不同的AR信号结果,取决于雄激素剂量和AR形状.
结论:
- 目前针对AR抑制的治疗策略可能存在固有的局限性,原因是雄激素的复杂,剂量依赖的作用.
- 了解AR单体和二聚体/寡聚体功能的理解为开发针对前列腺癌的向治疗提供了新的途径.
- 这项研究提供了对雄激素病的关键见解,并为开发新型治疗方式提供了信息.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
01:26Testosterone: Functions and Regulation
580
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
580
01:23Regulation of Expression at Multiple Steps
875
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
875
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K